TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
Volume 0.00M
Average 0.81M
TCRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
TScan Therapeutics, Inc.NASDAQ: TCRX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 16.9% from a year ago
Cash & equivalents stood at $128.06M at the end of Q1 FY2026, down 16.9% from a year earlier and down 16.0% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.
Context
- Cash & equivalents amounted to 63.4% of total assets at the end of Q1 FY2026, up 17.1 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -16.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 152.41M USD
- Year-over-year change
- -14.7%
- 4-year CAGR
- -1.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 152.41M | -14.7% |
| FY2024 | 2024-12-31 | 178.69M | +34.0% |
| FY2023 | 2023-12-31 | 133.36M | +11.1% |
| FY2022 | 2022-12-31 | 120.03M | -25.6% |
| FY2021 | 2021-12-31 | 161.41M | — |
Cash & Equivalents vs competitors
How TCRX compares with its peers on the latest reported figures
- TCRX's Mar 2026 cash & equivalents of $128.06M is the 3rd highest of the 10 companies compared; the peer median is $39.13M.
- Its year-over-year change of -16.9% is the 8th highest of 10, against a peer median of +35.2%.
- Cash & equivalents amounts to 63.4% of total assets for TCRX, versus a peer median of 40.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $255.84M | +180.1% | -23.6% | 71.7% | |
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $128.06M | -16.9% | +8.3% | 63.4% | |
| Mar 2026 | $115.46M | -25.9% | -7.2% | 82.6% | |
| Mar 2026 | $50.75M | +76.8% | +6.9% | 28.2% | |
| Mar 2026 | $39.13M | -23.8% | -29.5% | 40.5% | |
| Mar 2026 | $36.25M | +28.8% | -46.7% | 21.4% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M | -13.0% | +12.0% | 31.6% |
| Mar 2026 | $9.78M | +750.3% | -13.5% | 4.2% | |
| Apr 2026 | $4.01M | +35.2% | +32.1% | 58.1% | |
| Peer median (excluding TCRX) | $39.13M | +35.2% | -13.5% | 40.5% | |
Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 161.41M | 120.03M | 133.36M | 178.69M | 152.41M |
| Short-term Investments | 0 | 0 | 58.69M | 111.42M | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 4.25M | 4.1M | 2.19M | 2.61M | 4.8M |
| Total Current Assets | 165.65M | 124.13M | 194.24M | 292.72M | 157.21M |
| Property, Plant & Equipment (Net) | 17.26M | 69.2M | 71.23M | 71.6M | 66.45M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 5.2M | 5.04M | 0 | 0 | 5.03M |
| Tax Assets | 0 | 0 | 0 | 0 | 15.78M |
| Other Non-current Assets | 5.2M | 725K | 6.68M | 6.8M | (15.67M) |
| Total Non-current Assets | 22.45M | 74.96M | 77.91M | 78.4M | 71.58M |
| Total Assets | 188.11M | 199.09M | 272.15M | 371.12M | 228.79M |
| Account Payables | 1.77M | 2.91M | 2.37M | 4.28M | 1.24M |
| Short-term Debt | 1.65M | 3.68M | 3.35M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.41M | 3.87M | 10.14M | 11.7M | 2.62M |
| Other Current Liabilities | 3.92M | 2.48M | 5.9M | 6.92M | 4.34M |
| Total Current Liabilities | 21.34M | 17.31M | 29.82M | 35.96M | 18.7M |
| Long-term Debt | 0 | 29.29M | 26.7M | 32.07M | 32.53M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.5M | 0 | 5.62M | 1.25M | 0 |
| Other Non-current Liabilities | 97K | 49K | (1) | 135K | 0 |
| Total Non-current Liabilities | 5.99M | 82.35M | 91.46M | 94.19M | 86.97M |
| Total Liabilities | 27.33M | 99.66M | 121.28M | 130.15M | 105.67M |
| Common Stock | 3K | 3K | 5K | 6K | 5K |
| Retained Earnings | (92.16M) | (158.38M) | (247.6M) | (375.1M) | (504.86M) |
| Accumulated OCI | 0 | 0 | 0 | 51K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 160.78M | 99.43M | 150.87M | 240.97M | 123.12M |
| Total Debt | 6.04M | 85.98M | 92.43M | 97.38M | 94.14M |
| Net Debt | (155.36M) | (34.04M) | (40.93M) | (81.31M) | (58.27M) |
TScan Therapeutics, Inc.
NASDAQ:TCRX
Intrinsic Alpha fair value
Locked
Current Price
$0.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.